https://www.selleckchem.com/pr....oducts/epacadostat-i
lar GLASS grades (1.81±0.40 vs. 0.86±0.41, P0.0001) but lower Femoropopliteal Glass grades (0.73±1.10 vs. 2.43±1.71, P0.0001) than patients who were not candidates. There was no significant difference in GLASS stage between these two groups (P=0.368). After mean follow-up of 48months, there was no difference in mortality between both groups (40% vs. 32.1%, P=0.567). Among patients considered for revascularization, 23.2% had favorable angiography and 14.7% could have benefited for pDVA as a new therapeutic modality
Like
Comment
Share
